Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

$Vanda Pharmaceuticals (VNDA.US)$ WASHINGTON, Jan. 31, 2024 ...

$Vanda Pharmaceuticals(VNDA.US)$ WASHINGTON, Jan. 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.
Onychomycosis, or tinea unguium, is a fungal infection of the nail. Onychomycosis can result in discoloration of the nail, onycholysis (nail separation from the nail bed), and nail plate thickening. Onychomycosis accounts for one half of all nail disease with an estimated U.S. prevalence of up to 14%.1 In addition to cosmetic issues, onychomycosis infection may indirectly decrease peripheral circulation, thereby worsening conditions such as venous stasis and diabetic foot ulcers.2
"The initiation of clinical studies with VTR-297 in the treatment of onychomycosis is an important milestone in studying and developing potential new therapies for this common disorder," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
Translate
Report
4144 Views
Comment
Sign in to post a comment
1794Followers
29Following
21KVisitors
Follow